Metabolomic profiling as a useful tool for diagnosis and treatment of chronic disease: Focus on obesity, diabetes and cardiovascular diseases

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 1, 2013, Pages 61-68

  Kim, Oh Yoen ^a,b   Lee, Jong Ho ^b   Sweeney, Gary ^c  

^a Dong A University   (South Korea)

^b Yonsei University   (South Korea)

^c YORK UNIVERSITY   (Canada)

Author keywords

cardiovascular disease; chronic disease; diabetes; diagnostic; metabolomics; obesity; plasma metabolic profiling; therapeutic

Indexed keywords

ANTIDIABETIC AGENT; AROMATIC AMINO ACID; BRANCHED CHAIN AMINO ACID; CYTOKINE; FATTY ACID; LYSOPHOSPHATIDYLCHOLINE; METFORMIN; PHENYLALANINE; TRYPTOPHAN;

AGING; ARTERIAL STIFFNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATABOLISM; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENETIC ASSOCIATION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID PEROXIDATION; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; OXIDATIVE STRESS; PERSONALIZED MEDICINE; PHENOTYPE; PROGNOSIS; REVIEW; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLOMICS; OBESITY; OVERWEIGHT; PREDIABETIC STATE;

EID: 84871579721     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.121     Document Type: Review

References (63)

1. Sowers Jr. Obesity as a cardiovascular risk factor. Am. J. Med. 115(SUPPL8A), S37-S41 (2003
2. Roger VL, Go AS, Lloyd-Jones DM et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation 125(1), e2-e220 (2012
3. National Health and Nutrition Examination Survey (NHANES) 2007-2008. : Centers for Disease Control and Prevention (2011
4. The World Health Report: Health systems financing. World Health Organization, Geneva, Switzerland. (2012
5. Watson KE, Fonarow GC. The past, present, and future of statin therapy. Rev. Cardiovasc. Med. 6(3), 129-139 (2005
6. Rosenblit PD. Do persons with diabetes benefit from combination statin and fibrate therapy? Curr. Cardiol. Rep. 14(1), 112-124 (2012
7. Chokrungvaranon N, Deer J, Reaven PD. Intensive glycemic control and cardiovascular disease: Are there patients who may benefit? Postgrad. Med. 123(6), 114-123 (2011
8. Kim JY, Park JY, Kim OY et al. Metabolic profiling of plasma in overweight/obese and lean men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC-Q-TOF MS). J. Proteome Res. 9(9), 4368-4375 (2010
9. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 29(11), 1181-1189 (1999
10. Weckwerth W. Metabolomics in systems biology. Annu. Rev. Plant Biol. 54, 669-689 (2003
11. Newgard CB, An J, Bain JR et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 9(4), 311-326 (2009
12. Williams R, Lenz EM, Wilson AJ et al. A multi-analytical platform approach to the metabonomic analysis of plasma from normal and Zucker (fa/fa) obese rats. Mol. Biosyst. 2(3-4), 174-183 (2006
13. Serkova NJ, Jackman M, Brown JL et al. Metabolic profiling of livers and blood from obese Zucker rats. J. Hepatol. 44(5), 956-962 (2006
14. Shearer J, Duggan G, Weljie A, Hittel DS, Wasserman DH, Vogel HJ. Metabolomic profiling of dietary-induced insulin resistance in the high fat-fed C57BL/6J mouse. Diabetes. Obes. Metab. 10(10), 950-958 (2008
15. Zhang X, Wang Y, Hao F et al. Human serum metabonomic analysis reveals progression axes for glucose intolerance and insulin resistance statuses. J. Proteome Res. 8(11), 5188-5195 (2009
16. Bao Y, Zhao T, Wang X et al. Metabonomic variations in the drug-treated Type 2 diabetes mellitus patients and healthy volunteers. J. Proteome Res. 8(4), 1623-1630 (2009
17. Brindle JT, Antti H, Holmes E et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat. Med. 8(12), 1439-1444 (2002
18. Hollywood K, Brison DR, Goodacre R. Metabolomics: Current technologies and future trends. Proteomics 6(17), 4716-4723 (2006
19. Jordan KW, Cheng LL. NMR-based metabolomics approach to target biomarkers for human prostate cancer. Expert Rev. Proteomics 4(3), 389-400 (2007
20. Lindon JC, Holmes E, Nicholson JK. Pattern recognition methods and applications in biomedical magnetic resonance. Prog. NMR Spectrosc. 39, 1-40 (2001
21. Reo NV. NMR-based metabolomics. Drug Chem. Toxicol. 25(4), 375-382 (2002
22. Roy SM, Anderle M, Lin H, Becker CH. Differential expression profiling of serumproteins and metabolites for biomarker discovery. Int. J. Mass Spectrom. 238, 163-171 (2004
23. Yang J, Xu G, Zheng Y et al. Strategy for metabonomics research based on highperformance liquid chromatography and liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. A 1084(1-2), 214-221 (2005
24. Maurer HH. Liquid chromatography-mass spectrometry in forensic and clinical toxicology. J. Chromatogr. B Biomed. Sci. Appl. 713(1), 3-25 (1998
25. Idborg H, Zamani L, Edlund PO, Schuppe-Koistinen I, Jacobsson SP. Metabolic fingerprinting of rat urine by LC/MS Part 2. Data pretreatment methods for handling of complex data. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 828(1-2), 14-20 (2005
26. Benavente F, van der Heijden R, Tjaden UR, van der Greef J, Hankemeier T. Metabolite profiling of human urine by CE-ESIMS using separation electrolytes at low pH. Electrophoresis 27(22), 4570-4584 (2006
27. Wilson ID, Plumb R, Granger J, Major H, Williams R, Lenz EM. HPLC-MS-based methods for the study of metabonomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 817(1), 67-76 (2005
28. Toyo'oka T. Determination methods for biologically active compounds by ultra-performance liquid chromatography coupled with mass spectrometry: Application to the analyses of pharmaceuticals, foods, plants, environments, metabonomics, and metabolomics. J. Chromatogr. Sci. 46(3), 233-247 (2008
29. Govorukhina NI, Reijmers TH, Nyangoma SO, van der Zee AG, Jansen RC, Bischoff R. Analysis of human serum by liquid chromatography-mass spectrometry: Improved sample preparation and data analysis. J. Chromatogr. A 1120(1-2), 142-150 (2006
30. Major HJ, Williams R, Wilson AJ, Wilson ID. A metabonomic analysis of plasma from Zucker rat strains using gas chromatography/ mass spectrometry and pattern recognition. Rapid Commun. Mass Spectrom. 20(22), 3295-3302 (2006
31. Yuan K, Kong H, Guan Y, Yang J, Xu G. A GC-based metabonomics investigation of type 2 diabetes by organic acids metabolic profile. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 850(1-2), 236-240 (2007
32. Wilson ID, Nicholson JK, Castro-Perez J et al. High resolution 'ultra performance' liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J. Proteome Res. 4(2), 591-598 (2005
33. O'Connor D, Mortishire-Smith R. High-throughput bioanalysis with simultaneous acquisition of metabolic route data using ultra performance liquid chromatography coupled with time-offlight mass spectrometry. Anal. Bioanal. Chem. 385(1), 114-121 (2006
34. Huffman KM, Shah SH, Stevens RD et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 32(9), 1678-1683 (2009
35. Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to diabetes research: Moving from information to knowledge. Diabetes 58(11), 2429-2443 (2009
36. Zhao X, Peter A, Fritsche J et al. Changes of the plasma metabolome during an oral glucose tolerance test: Is there more than glucose to look at? Am. J. Physiol. Endocrinol. Metab. 296(2), E384-E393 (2009
37. Ha CY, Kim JY, Paik JK et al. The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed Type 2 diabetes. Clin. Endocrinol. (Oxf.) 76(5), 674-682 (2012
38. Huo T, Cai S, Lu X, Sha Y, Yu M, Li F. Metabonomic study of biochemical changes in the serum of Type 2 diabetes mellitus patients after the treatment of metformin hydrochloride. J. Pharm. Biomed. Anal. 49(4), 976-982 (2009
39. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr. Opin. Cardiol. 21(1), 1-6 (2006
40. Galili O, Versari D, Sattler KJ et al. Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 292(2), H904-H911 (2007
41. Wang TJ, Larson MG, Vasan RS et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 17(4), 448-453 (2011
42. Chen L, Liang B, Froese DE et al. Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: Effect of lysophosphatidylcholine composition on vascular relaxation. J. Lipid Res. 38(3), 546-553 (1997
43. Nelson GJ. The phospholipid composition of plasma in various mammalian species. Lipids 2(4), 323-328 (1967
44. Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: Mediators of endothelial dysfunction and atherosclerosis. Med. Sci. Monit. 12(1), RA5-R16 (2006
45. Ojala PJ, Hermansson M, Tolvanen M et al. Identification of α-1 acid glycoprotein as a lysophospholipid binding protein: A complementary role to albumin in the scavenging of lysophosphatidylcholine. Biochemistry 45(47), 14021-14031 (2006
46. Koves TR, Li P, An J et al. Peroxisome proliferator-activated receptorgamma co-activator 1α-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J. Biol. Chem. 280(39), 33588-33598 (2005
47. Koves TR, Ussher JR, Noland RC et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 7(1), 45-56 (2008
48. Van Hove JL, Zhang W, Kahler SG et al. Mediumchain acyl-CoA dehydrogenase (MCAD) deficiency: Diagnosis by facylcarnitine analysis in blood. Ame. J. Human Genet. 52, 958-966 (1993
49. Krebs M, Krssak M, Bernroider E et al. Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes 51(3), 599-605 (2002
50. Kampus P, Kals J, Ristimäe T et al. Augmentation index and carotid intimamedia thickness are differently related to age, C-reactive protein and oxidized low-density lipoprotein. J. Hypertens. 25(4), 819-825 (2007
51. Byfield FJ, Tikku S, Rothblat GH, Gooch KJ, Levitan I. OxLDL increases endothelial stiffness, force generation, and network formation. J. Lipid Res. 47(4), 715-723 (2006
52. Brinkley TE, Nicklas BJ, Kanaya AM et al. Plasma oxidized low-density lipoprotein levels and arterial stiffness in older adults: The Health, Aging, and Body Composition Study. Hypertension 53(5), 846-852 (2009
53. Scuteri A, Orru M, Morrell C et al. Independent and additive effects of cytokine patterns and the metabolic syndrome on arterial aging in the SardiNIA Study. Atherosclerosis 215(2), 459-464 (2011
54. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 25(5), 932-943 (2005
55. Nevedomskaya E, Meissner A, Goraler S et al. Metabolic profiling of accelerated aging ERCC1 d/- mice. J. Proteome Res. 9(7), 3680-3687 (2010
56. Yan S, Wu B, Lin Z et al. Metabonomic characterization of aging and investigation on the anti-aging effects of total flavones of Epimedium. Mol. Biosyst. 5(10), 1204-1213 (2009
57. Matsuoka O, Otsuka K, Murakami S et al. Arterial stiffness independently predicts cardiovascular events in an elderly community - Longitudinal Investigation for the Longevity and Aging in Hokkaido County (LILAC) study. Biomed. Pharmacother. 59(SUPPL1), S40-S44 (2005
58. Laurent S, Boutouyrie P, Asmar R et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37(5), 1236-1241 (2001
59. Yamashina A, Tomiyama H, Takeda K et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens. Res. 25(3), 359-364 (2002
60. Hung CS, Lin JW, Hsu CN et al. Using brachial-ankle pulse wave velocity to associate arterial stiffness with cardiovascular risks. Nutr. Metab. Cardiovasc. Dis. 22, 1-6 (2008
61. Mosedale DE, Smith DJ, Aitken S et al. Circulating levels of MCP-1 and eotaxin are not associated with presence of atherosclerosis or previous myocardial infarction. Atherosclerosis 183(2), 268-274 (2005
62. Suhre K, Shin SY, Petersen AK et al.; CARDIoGRAM. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477(7362), 54-60 (2011
63. Adamski J. Genome-wide association studies with metabolomics. Genome Med. 4(4), 34 (2012